CC
CCCC icon

Commodore Capital’s C4 Therapeutics CCCC Stock Holding History

Commodore Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,410,384
Closed -$19.4M – 35
2024
Q3 		$19.4M Hold
3,410,384
– – 1.21% 25
2024
Q2 		$15.8M Hold
3,410,384
– – 1.08% 25
2024
Q1 		$27.9M Sell
3,410,384
-389,616
-10% -$3.02M 1.86% 19
2023
Q4 		$21.5M Buy
+3,800,000
New +$8.66M 1.88% 20
2022
Q2 		– Sell
-481,094
Closed -$11.7M – 25
2022
Q1 		$11.7M Hold
481,094
– – 2.61% 15
2021
Q4 		$15.5M Hold
481,094
– – 3.59% 13
2021
Q3 		$21.5M Hold
481,094
– – 5.67% 5
2021
Q2 		$18.2M Hold
481,094
– – 6.34% 4
2021
Q1 		$17.8M Hold
481,094
– – 7.09% 2
2020
Q4 		$15.9M Buy
+481,094
New +$14M 8.67% 1

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Commodore Capital's CCCC Position: Q4 2024 in Review

Commodore Capital sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 3,410,384 shares — an estimated $19.4M sold.

Commodore Capital first reported a position in CCCC in Q4 2020 and held it in 10 quarters. The position peaked at $27.9M in Q1 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Commodore Capital reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Commodore Capital sold 3,410,384 C4 Therapeutics shares in Q4 2024, an estimated $19.4M.
  • Commodore Capital first reported a position in C4 Therapeutics in Q4 2020 and held it in 10 quarters.
  • Commodore Capital's C4 Therapeutics position peaked at $27.9M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Commodore Capital's 13F filing for Q4 2024, filed 14 Feb 2025.